Inventor
LIAO HUA-XIN
US40 patents
⚠️ This page may combine multiple inventors who share the name “LIAO HUA-XIN”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
UNIV DUKE
26 patentsUS5863540AJan 26, 1999
Adhesion molecule
UNIV DUKE23 citations89
US10004800B2Jun 26, 2018
Antibody evolution immunogens
UNIV DUKE6 citations82
US7033593B2Apr 25, 2006
Immunogen comprising an HIV envelope protein, a ligand and H2 peptide
UNIV DUKE11 citations82
US11136380B2Oct 5, 2021
Anti-complement factor H antibodies
UNIV DUKE6 citations81
US10183988B2Jan 22, 2019
Anti-Complement factor H antibodies
UNIV DUKE7 citations79
US10450368B2Oct 22, 2019
HIV-1 neutralizing antibodies and uses thereof (CD4bs antibodies)
UNIV DUKE5 citations72
US9821053B2Nov 21, 2017
Human Immunodeficiency Virus type 1 group M consensus and mosaic envelope glycoproteins
UNIV DUKE2 citations72
US9717789B2Aug 1, 2017
Liposome-peptide conjugate and method of using same to induce production of anti-HIV antibodies
UNIV DUKE2 citations72
US7101552B2Sep 5, 2006
Immunogen comprising an HIV envelope protein, a ligand and H2 peptide
UNIV DUKE9 citations72
US7070787B2Jul 4, 2006
Method of inducing the production of antibodies to HIV
UNIV DUKE10 citations72
US6544747B2Apr 8, 2003
Assay system
UNIV DUKE7 citations72
US10968255B2Apr 6, 2021
Compositions comprising HIV envelopes to induce CH235 lineage antibodies
UNIV DUKE2 citations71
US10865238B1Dec 15, 2020
Complement factor H antibodies
UNIV DUKE5 citations68
US11071783B2Jul 27, 2021
HIV-1 neutralizing antibodies and uses thereof
UNIV DUKE2 citations67
US11884704B2Jan 30, 2024
Compositions comprising HIV envelopes to induce CH235 lineage antibodies
UNIV DUKE0 citations60
US12286471B2Apr 29, 2025
Inhibitors of complement factor H
UNIV DUKE0 citations59
US11897946B2Feb 13, 2024
Methods of inhibiting complement factor H (CFH) comprising administering an antibody that binds CFH
UNIV DUKE0 citations59
US10946090B2Mar 16, 2021
Consensus/ancestral immunogens
UNIV DUKE0 citations59
US11077130B2Aug 3, 2021
Methods for reducing HIV-1 mother-to-child transmission by inducing V3-specific or CD4 binding site-specific antibodies
UNIV DUKE0 citations56
US10849970B2Dec 1, 2020
Antibody evolution immunogens
UNIV DUKE0 citations51
US10588960B2Mar 17, 2020
Liposome-peptide conjugate and method of using same to induce production of anti-HIV antibodies
UNIV DUKE0 citations51
US10232034B2Mar 19, 2019
Compositions comprising CH505 envelopes, and trimers
UNIV DUKE0 citations51
US10561725B2Feb 18, 2020
Method of inducing the production of protective anti-HIV-1 antibodies
UNIV DUKE0 citations48
US10344077B2Jul 9, 2019
HIV-1 neutralizing antibodies and uses thereof (V3 antibodies)
UNIV DUKE0 citations47
US11944681B2Apr 2, 2024
HIV-1 neutralizing antibodies and uses thereof
UNIV DUKE0 citations46
US10286057B2May 14, 2019
Cyclic HIV-1 Env V3 glycopeptide immunogens
UNIV DUKE0 citations46
HAYNES BARTON F
4 patentsUS8071107B2Dec 6, 2011
Nucleic acids encoding modified human immunodeficiency virus type 1 (HIV-1) group M consensus envelope glycoproteins
HAYNES BARTON F26 citations89
US9402893B2Aug 2, 2016
Liposome-peptide conjugate and method of using same to induce production of anti-HIV antibodies
HAYNES BARTON F5 citations82
US9844589B2Dec 19, 2017
Modified human immunodeficiency virus type 1 (HIV-1) group M consensus envelope glycoproteins capable of inducing broadly reactive T- and B-cell responses
HAYNES BARTON F2 citations70
US8956627B2Feb 17, 2015
Method of inducing antibodies to human immunodeficiency virus involving the administration of MPER peptide-liposome conjugates
HAYNES BARTON F2 citations61